Status:
COMPLETED
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pan...
Eligibility Criteria
Inclusion
- Pathologically confirmed adenocarcinoma of the pancreas
- Patient have undergone a potentially curative resection
- No previous irradiation to the planned field
- Negative pregnancy test for child bearing women
Exclusion
- Non-adenocarcinoma pancreatic cancer
- Treatment with any drug within the last 30 days that has not received regulatory approval.
- Serious systemic disorder
- Metastatic disease
- Pregnancy, breast feeding
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00191568
Start Date
October 1 2002
End Date
May 1 2007
Last Update
October 19 2007
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) MON-FRI 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Grenoble, France
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) MON-FRI 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Lyon, France
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) MON-FRI 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Marseille, France
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) MON-FRI 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Montpellier, France